行情

MBRX

MBRX

Moleculin
NASDAQ

实时行情|Nasdaq Last Sale

0.5643
-0.0112
-1.95%
交易中 14:49 04/02 EDT
开盘
0.5600
昨收
0.5755
最高
0.5801
最低
0.5510
成交量
51.68万
成交额
--
52周最高
3.150
52周最低
0.3230
市值
3,003.64万
市盈率(TTM)
-1.6505
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MBRX价格均价为3.333,最高价位5.00,最低价为2.000。

EPS

MBRX 新闻

更多
  • 特朗普宣称石油减产遭“打脸” 油价经历过山车行情
  • 新浪财经-自媒体综合 · 34分钟前
  • 午后:油价大起大落 美股涨幅收窄
  • 新浪美股 · 51分钟前
  • 美联储Kashkari称美国经济“几乎肯定”正陷入衰退
  • 新浪美股 · 1小时前
  • 上周初请失业金人数倍增 美国就业市场究竟发生了什么?
  • FX168 · 1小时前

所属板块

制药
+0.90%
制药与医学研究
+0.93%

热门股票

代码
价格
涨跌幅

MBRX 简况

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
展开

微牛提供Moleculin Biotech Inc(NASDAQ-MBRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MBRX股票新闻,以帮助您做出投资决策。